NCT01834911 - Effect of Tetrabenazine on Stroop Interference in HD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 1, 2018

Study Completion Date

January 1, 2018

Conditions

Huntington Disease

Interventions

DRUG

Tetrabenazine withdrawal

Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.

Trial Locations (1)

10029

Terence Cardinal Cooke Health Care Center, New York